Kolexia
Garderet Laurent Hématologie
Garderet Laurent
Hématologie
Hôpital Pitie Salpetriere
Paris, France
349 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Myélome multiple Tumeurs à plasmocytes Récidive tumorale locale Aberrations des chromosomes Maladie résiduelle Paraprotéinémies Lymphomes Leucémies Maladie du greffon contre l'hôte

Collaborateurs

Voir plus
Moreau Philippe
Moreau Philippe
Hôpital Hôtel-Dieu Nantes, Nantes, France
Caillot Denis
Caillot Denis
Clinique Mutualiste Benigne Joly, Talant, France
Leleu Xavier
Leleu Xavier
Hôpital La Miletrie, Poitiers, France
Hulin Cyrille
Hulin Cyrille
Hôpital Haut-lévêque, Pessac, France

Industries

Voir plus
Janssen
19 collaboration(s)
Dernière en 2023
Zeste Research
18 collaboration(s)
Dernière en 2021
Amgen
17 collaboration(s)
Dernière en 2023
Sanofi
16 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma: A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy After Autologous Stem Cell Transplantation (ASCT) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) (EXCALIBER-Maintenance)
Essai Clinique (BMS)   20 mars 2024
EXCALIBER-RRMM: A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM)
Essai Clinique (Celgene)   12 mars 2024
The role of maintenance therapy following autologous stem cell transplantation in newly diagnosed multiple myeloma: Considerations on behalf of the Chronic Malignancies Working Party of the EBMT.
British journal of haematology   23 février 2024
In the era of Bortezomib-based Induction, intensification of Melphalan-based conditioning with Bortezomib does not improve Survival Outcomes in newly diagnosed Multiple Myeloma: a study from the Chronic Malignancies Working Party of the EBMT.
Bone marrow transplantation   31 janvier 2024
Low non-relapse mortality and good haematological and renal responses after autologous haematopoietic stem cell transplantation in multiple myeloma patients with renal insufficiency at transplant: A prospective Société Francophone de Greffe de Moelle-Thérapie Cellulaire observational study.
British journal of haematology   12 novembre 2023
Cryopreserved Versus Non-Cryopreserved Peripheral Blood Haematopoietic Stem Cells for Autologous Stem Cell Transplantation in Multiple Myeloma: A Comparative Analysis from the Chronic Malignancies Working Party of EBMT and WBMT
65th ASH Annual Meeting Abstracts   02 novembre 2023
Long Term Outcomes and Renal Response Following Autologous Stem Cell Transplantation for Light Chain Deposition Disease:a Retrospective Study on Behalf of the Cmwp of the EBMT
65th ASH Annual Meeting Abstracts   02 novembre 2023
Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group.
The Lancet. Oncology   10 juillet 2023
PCD: A Multicenter Open Label Phase II Study of Pomalidomide and Cyclophosphamide and Dexamethasone in Relapse/Refractory Multiple Myeloma Patients Who Were First Treated Within the IFM/DFCI 2009 Trial
Essai Clinique (Celgene)   03 juillet 2023
Impact of viral hepatitis therapy in multiple myeloma and other monoclonal gammopathies linked to hepatitis B or C viruses.
Haematologica   18 mai 2023